Who is sponsoring NCT02910635?

NCT02910635 is sponsored by Ionis Pharmaceuticals, Inc..

What drugs are being tested in NCT02910635?

Interventions in NCT02910635: Volanesorsen, Moxifloxacin, Placebo.

What condition does NCT02910635 study?

NCT02910635 studies Abnormalities, Cardiovascular.

Is NCT02910635 still recruiting?

NCT02910635 is currently completed. Last updated 28 January 2022.

Last reviewed 2022-01-28 · How we verify

NCT02910635

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers

Completed Phase 1 Last updated 28 January 2022

What this trial tests

Phase 1 trial testing Volanesorsen in Abnormalities, Cardiovascular in 52 participants. Completed in 20 December 2016.

Timeline

19 September 2016

Primary endpoint
20 December 2016

20 December 2016

Quick facts

Lead sponsor	Ionis Pharmaceuticals, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	other
Enrollment	52
Start date	19 September 2016
Primary completion	20 December 2016
Estimated completion	20 December 2016
Sites	1 location across United States

Drugs / interventions tested

Volanesorsen — full drug profile →
Moxifloxacin (moxifloxacin) — full drug profile →
Placebo

Conditions studied

Abnormalities, Cardiovascular — all drugs for Abnormalities, Cardiovascular →

Sponsor

Ionis Pharmaceuticals, Inc. — full company profile →

Who can join

Adults 18 to 55, any sex, with Abnormalities, Cardiovascular. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to assess the corrected QT interval (QTc) effect of volanesorsen (ISIS 304801) administered as a 300 mg subcutaneous (SC) therapeutic and a 300 mg intravenous (IV; 2-hour infusion) supra-therapeutic dose relative to placebo in healthy adult male and female subjects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Current RNA strategies in treating cardiovascular diseases.
Chia SPS, Pang JKS, Soh BS. · · 2024 · cited 13× · PMID 38291757 · DOI 10.1016/j.ymthe.2024.01.028

Verify or expand the search:

Other trials of Volanesorsen

Trials testing the same drug.

NCT02658175 — The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomic · Phase 3 · completed
NCT02300233 — The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia · Phase 3 · completed
NCT03544060 — Volanesorsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS) · no longer available

Other Ionis Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT06673069 — Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Par · Phase 1 · terminated
NCT06014541 — Observational Study to Characterize Biomarkers and Disease Progression in Participants With Methyl CpG Binding Protein 2 · terminated
NCT05610280 — A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, · Phase 3 · completed
NCT05579860 — A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healt · Phase 1 · completed
NCT05552326 — A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02910635 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ionis Pharmaceuticals, Inc.
Last refreshed: 28 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02910635.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing